Novartis and Microsoft bring AI & Deep Bioscience to Transform Medicine

Novartis and Microsoft bring AI & Deep Bioscience to Transform Medicine

Novartis recently announced the launch of the Novartis AI innovation lab and selected Microsoft as an AI and data-science partner.

Novartis is betting big on data and digital transformation as a key strategic pillar to maintain itself as a leading medicine company powered by advanced therapies and data science.

Microsoft in blogpost noted that the average cost to introduce any new prescription drugs for life sciences companies is $2.6 billion.

Executive Opinion 

CEO of Novartis, Vas Narasimhan, said, "As Novartis continues evolving into a focused medicines company powered by advanced therapy platforms and data science, alliances like this will help us deliver on our purpose to reimagine medicine to improve and extend patients’ lives. Pairing our deep knowledge of human biology and medicine with Microsoft’s leading expertise in AI could transform the way we discover and develop medicines for the world."

Microsoft CEO, Satya Nadella, added, "Our strategic alliance will combine Novartis' life sciences expertise with the power of Azure and Microsoft AI. Together, we aim to address some of the biggest challenges facing the life sciences industry today and bring AI capabilities to every Novartis employee so they can unlock new insights as they work to discover new medicines and reduce patient costs."

Novartis and Microsoft partnership for AI

In a blogpost, Corporate Vice President, Microsoft Healthcare, Peter Lee noted three areas where Microsoft will collaborate with Novartis.  The first area is a personalized treatment for macular degeneration causing irreversible blindness. The second area is leveraging Artificial Intelligence to increase the efficiency of manufacturing the new gene and cell therapies. Initial efforts will focus on acute lymphoblastic leukemia. The third focus area is to utilize Microsoft developed neural networks to automatically generate, screen and select promising molecules required for new medicines designs.

The multiyear partnership will address AI empowerment and AI exploration objectives. Novartis plans to bring AI to every associate within the company to create new AI models by leveraging vast Novartis datasets and Microsoft’s advanced AI solutions.

Novartis also plans to address hardest computational challenges within life sciences. Examples include challenges in generative chemistry, image segmentation & analysis for smart and personalized delivery of therapies and optimization of cell and gene therapies at scale.

In July, Microsoft and OpenAI also partnered to extend Microsoft Azure’s capabilities in large-scale AI systems. OpenAI planned to bring its services to the Microsoft Azure platform and these services would be utilized to create new AI technologies.


Note: We at TechSutram take our ethics very seriously. More information about it can be found here.
Mandar Pise Opinions expressed by techsutram contributors are their own. More details

Mandar is a seasoned software professional for more than a decade. He is Cloud, AI, IoT, Blockchain and Fintech enthusiast. He writes to benefit others from his experiences. His overall goal is to help people learn about the Cloud, AI, IoT, Blockchain and Fintech and the effects they will have economically and socially in the future.

No comments:

Post a Comment

    Your valuable comments are welcome. (Moderated)